This study investigates the role of Delta-like ligand 3 (DLL3) in modulating Notch signaling in small cell lung cancer (SCLC). Using a mouse model with Rosa26-targeted, inducible DLL3 expression, researchers showed that DLL3 suppresses Notch signaling, alters tumor cell fate, and increases intratumoral heterogeneity. The model enabled precise analysis of DLL3’s contribution to neuroendocrine differentiation and its potential as a therapeutic target.
Inducible DLL3 expression suppresses Notch signaling, reshapes tumor differentiation, and enhances heterogeneity in SCLC; DLL3 is validated as a regulator and therapeutic target.
Rosa26 Knockin mouse model with Cre-inducible expression of DLL3 using IRES technology, allowing bicistronic expression with a reporter.
Small cell lung cancer, Notch signaling, Tumor heterogeneity, Neuroendocrine tumors
Rosa26 Knockin, IRES-reporter, Inducible expression, DLL3, Cre-lox
From model design to experimental results
Featured in 600+ scientific articles
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Generated with biopharma partners and in-house
and guaranteed freedom to operate
Models with certified health status from professional breeders in US and Europe
